Related references
Note: Only part of the references are listed.Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein?derived peptides
Michelle P. Aranha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study
Elodie Pastural et al.
VACCINE (2020)
Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial
Silvana Sekuloski et al.
PLOS ONE (2018)
Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Streptococcus pyogenes
Sanaz Salehi et al.
MSPHERE (2018)
Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015
David A. Watkins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Structure-based design of broadly protective group a streptococcal M protein-based vaccines
James B. Dale et al.
VACCINE (2017)
Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity
Hannah R. Frost et al.
CLINICAL INFECTIOUS DISEASES (2017)
An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene
Zhiwu Sun et al.
EMERGING MICROBES & INFECTIONS (2016)
Conserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding protein
Cosmo Z. Buffalo et al.
NATURE MICROBIOLOGY (2016)
Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus
Mark J. Walker et al.
CLINICAL MICROBIOLOGY REVIEWS (2014)
A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development
Martina Sanderson-Smith et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Factor H Binds to the Hypervariable Region of Many Streptococcus pyogenes M Proteins but Does Not Promote Phagocytosis Resistance or Acute Virulence
Mattias C. U. Gustafsson et al.
PLOS PATHOGENS (2013)
New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
James B. Dale et al.
VACCINE (2011)
Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes
Thomas A. Penfound et al.
VACCINE (2010)
Global emm type distribution of group A streptococci: systematic review and implications for vaccine development
Andrew C. Steer et al.
LANCET INFECTIOUS DISEASES (2009)
Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines
Huynh-Hoa Bui et al.
BMC BIOINFORMATICS (2007)
Prediction of continuous B-cell epitopes in an antigen using recurrent neural network
Sudipto Saha et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2006)
The global burden of group A streptococcal diseases
JR Carapetis et al.
LANCET INFECTIOUS DISEASES (2005)
Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers
SA McNeil et al.
CLINICAL INFECTIOUS DISEASES (2005)
Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections
MA Hall et al.
INFECTION AND IMMUNITY (2004)
Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults - Phase 1 trial
KL Kotloff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity
WL Liu et al.
VACCINE (2004)
Immunogenicity of a 26-valent group A streptococcal vaccine
MC Hu et al.
INFECTION AND IMMUNITY (2002)